Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization: GRI Bio (GRI)
This chart of the EV/EBITDA multiple for GRI Bio, Inc. (GRI) shows a level of 0.00. GRI Bio, Inc. (GRI) is developing a comprehensive NKT-cell-based therapy system to prevent tissue degradation in fibrosis. Long-term contracts with bio-factories guarantee the raw material supply, eliminating the risk of shortages. The business is currently focusing on primary safety trials of new molecules within early-stage clinical research.
GRI (gribio.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Capital GRI Bio, Inc.|GRI - Long-Term Liabilities to Capital|Short-Term Debt to Capital GRI Bio|GRI - Company Total Indebtedness|Debt to Book Capitalization Ratio GRI Bio Corporation|GRI - Company Long-Term Loans and Borrowings|Company Short-Term Debts GRI Bio|Quick Liquidity Indicator gribio.com
- net income and valuation multiples indicators:
GRI - Final Profit|Projected Future Earnings GRI Bio, Inc.|GRI - Price to Earnings Ratio|Forward P/E Multiple GRI Bio, Inc.|GRI - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GRI Bio Corporation|GRI - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months GRI Bio|GRI - Earnings per share for the trailing year|Quarterly EPS earnings growth gribio.com|GRI - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year GRI Bio, Inc.
Basic company analysis:GRI (GRI Bio Corp)
For the high-tech business of GRI Bio, Inc. (GRI), aligning the enterprise value with its operational efficiency is critical. By analyzing the EV/EBITDA multiple over time, an investor assesses the ability of earnings to cover total capital and debt obligations without tax distortions. Amid stringent FDA filters, the stability of this metric confirms the company's financial resilience while NKT-therapy patents transform into actual cash flow.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Argenx ARGX|BNTX - Enterprise Value to EBITDA Ratio|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|PTGX (Protagonist) - Enterprise Value to EBITDA Ratio|Immunovant Inc (IMVT) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kiniksa Pharmaceuticals Ltd|Enterprise Value to Operating Income Before Depreciation GRFS (Grifols Biemat)|EV/EBITDA Multiple ADPT|CLDX - Company Value to EBITDA|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|Enterprise Value to EBITDA Multiple BioCryst Pharmaceuticals, Inc.|VERA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation DNTH (Dianthus Corp)|PHVS: EV/EBITDA Multiple|ABCL - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TRML|PGEN: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple PHAR|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKTR (Nektar Corp)|EV/EBITDA Multiple UPB (Upstream Bio Inc)|Total Company Value to Operating Income Before Depreciation Ratio zenasbio.com (ZBIO)|IMNM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Gossamer Bio Inc|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|Septerna Pharma - Business Value to Operating Income Before Depreciation|PVLA (Pieris Pharmaceuticals) - EV/EBITDA Multiple|savarapharma.com (SVRA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rigel Pharmaceuticals, Inc. (RIGL)|AnaptysBio Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATXS (Astria Pharma)|ENGN - Enterprise Value to EBITDA Ratio|RAPT: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Aerovate Therapeutics Inc JBIO|ACRS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Kyverna Therapeutics Inc. KYTX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tiziana Life Sciences PLC|CABA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VTYX|Total Company Value to Operating Income Before Depreciation Ratio theratech.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avalo Therapeutics AVTX|ELDN (Eledon Pharmaceuticals Inc.) - Company Value to Operating Income Before Depreciation Ratio|Agenus Inc - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CLYM (Climb Bio, Inc)|ZURA: EV/EBITDA Multiple|atyrpharma.com (ATYR) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adagene Inc|IMA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Shattuck Labs, Inc. (STTK)|Enterprise Value to EBITDA Ratio equilliumbio.com EQ|EV/EBITDA Multiple CNTB (Connect Biopharma Holdings Limited)|EV/EBITDA Multiple Immunic Therapeutics IMUX|ATRA: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation IFRX (InflaRx N.V.)|XFOR: EV/EBITDA Multiple|ACET - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Celularity Inc|Enterprise Value to EBITDA Ratio inmunebio.com (INMB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Barinthus Biotherapeutics plc (BRNS)|Enterprise Value to EBITDA Ratio Kezar Life Sciences Inc. KZR|SAB Biotherapeutics, Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Akari Therapeutics, Plc AKTX|ENLV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|QTTB (Q32 Bio Inc.) - Enterprise Value to Operating Income Before Depreciation|GOVX: EV/EBITDA Multiple|Company Value to EBITDA Edesa Biotech Inc (EDSA)|IBIO (iBio Corp) - EV/EBITDA Multiple|CARM - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization XTL Biopharmaceuticals (XTLB)|BOLT (boltbio.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple HCWB (HCW Biologics)|Total Company Value to Operating Income Before Depreciation Ratio Aptevo Therapeutics, Inc. (APVO)|AIM: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ADTX (Aditxt)|XRTX: EV/EBITDA Multiple|HIND (reshapelifesciences.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|REVB (Revelation Biosciences, Inc.) - EV/EBITDA Multiple|Indaptus Therapeutics Inc (INDP) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Scinai (SCNI)|CALI - Company Value to EBITDA|Affimed N.V. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALLK|HOOKIPA - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio IGM Biosciences, Inc. IGMS|iTeos (ITOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation OCEA|TCBP (TC Biopharm) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio thirdharmonicbio.com (THRD)
